Major Events - Cloudtop New Horizon (01952) has its original product, Nanfukang®, protected by patent ZL200980127272.5 in China, which is currently valid [1] - Linkang Biotechnology Group (00690) has reached a strategic cooperation with Wenzhou Medical University National Engineering Research Center and the People's Government of Ouhai District, Wenzhou [1] - Auhua Pharmaceutical (00013) announced that the new drug application for Savolitinib for treating gastric cancer patients with MET amplification has been accepted and included in priority review in China [1] - Fosun Pharma (02196) has initiated Phase I clinical trials for its integrated diagnosis and treatment nuclear medicine project SRT-007 within China [1] - Postal Savings Bank of China (01658) has received approval from the National Financial Supervision Administration for the absorption and merger with Postal Huai Wanjia Bank [1] - MicroPort Cardiac Devices-B (02160) has officially published the one-year follow-up results of the early feasibility study for AltaValveTM [1] Operating Performance - New Fire Technology Holdings (01611) reported an annual loss attributable to shareholders of HKD 9.212 million, a shift from profit to loss year-on-year [1] - Xingqian Development (00640) reported an annual net profit of approximately HKD 122 million, an increase of 21.7% year-on-year [1] - Zijin Mining Group (02899) expects a net profit attributable to shareholders of approximately RMB 51-52 billion for the fiscal year 2025, representing a year-on-year increase of about 59%-62% [1] - Zijin Gold International (02259) issued a profit warning, expecting a net profit attributable to shareholders of approximately USD 1.5-1.6 billion for 2025, a year-on-year increase of about 212%-233% [1]

Core Viewpoint - The announcement highlights the successful one-year follow-up results of the early feasibility study for the AltaValveTM transcatheter mitral valve replacement (TMVR) device developed by 4C Medical Technologies, Inc., indicating significant improvements in patient outcomes and safety [1] Group 1: Study Overview - The study involved 30 high-risk patients with symptomatic severe mitral regurgitation (MR) across multiple centers in Europe, the USA, and Japan [1] - Patients were divided into two groups: 13 underwent the transapical approach, while 17 used the transseptal approach [1] Group 2: Clinical Outcomes - The technical success rate of the procedure was reported at 97%, with complete elimination of MR in all patients [1] - The mean transvalvular pressure gradient decreased from 2.5 mmHg at baseline to 2.1 mmHg post-operation, indicating significant hemodynamic improvement [1] Group 3: Safety Profile - The one-year all-cause mortality rate was 17% for the transapical group and only 7% for the transseptal group, with no cases of cardiac-related mortality [1] - No adverse events such as stroke, new-onset atrial fibrillation, or mitral valve re-intervention were reported in the entire cohort [1] Group 4: Quality of Life Improvement - 96% of patients improved to NYHA functional class I-II at one year, reflecting a substantial enhancement in quality of life [1] Group 5: Regulatory Status - AltaValveTM received two breakthrough device designations from the FDA in 2024 and is currently conducting pivotal clinical studies in Europe and the USA under an FDA-approved Investigational Device Exemption (IDE) [1]

（ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2160） 自願公告 AltaValveTM早期可行性研究一年隨訪結果正式公佈 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 MicroPort CardioFlow Medtech Corporation 微創心通醫療科技有限公司 本公告乃由微創心通醫療科技有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願作出，以知會本公司股東及潛在投資者有關本集團最新業務進展。 本 公 司 董 事（「董 事」）會（「董事會」）欣 然 宣 佈，近 日，由 集 團 聯 營 公 司 4C Medical Technologies, Inc.（「4C Medical」）自主研發的AltaValveTM經導管二尖瓣置 換（「TMVR」）醫療器械（「AltaValveTM」）的早期可行性研究一年隨訪結果正式公 佈。 本次研究覆蓋歐洲、美國、日本多中心，納入患者30名，均為手術高風險、 伴有 ...